Introduction
Abemaxen 150 mg (Abemaciclib) is a highly potent, targeted oncology medication classified as a CDK4 and CDK6 inhibitor. Manufactured by Everest Pharmaceuticals Ltd. and supplied globally by Onco Solution, Abemaxen is a cornerstone therapy for advanced breast cancer. It works by blocking specific proteins that allow cancer cells to grow and divide rapidly. Unlike other inhibitors in its class, Abemaxen demonstrates a higher selectivity for CDK4, which is a primary driver in breast cancer proliferation, offering a powerful approach to slowing disease progression.
Indications
Abemaxen 150 mg (Abemaciclib) is indicated for:
- HR+/HER2- Early Breast Cancer: Adjuvant treatment of adult patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive early breast cancer at high risk of recurrence, used in combination with endocrine therapy (tamoxifen or an aromatase inhibitor).
- HR+/HER2- Advanced or Metastatic Breast Cancer:
- In combination with an aromatase inhibitor as initial endocrine-based therapy for postmenopausal women.
- In combination with fulvestrant for women with disease progression following endocrine therapy.
- As monotherapy for adult patients with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.
Pharmacology
Abemaciclib, the active ingredient in Abemaxen, is an oral, selective, small-molecule inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6).
- Mechanism: It prevents the phosphorylation of the Retinoblastoma (Rb) protein. By blocking Rb phosphorylation, it halts the progression of the cell cycle from the G1 phase to the S phase.
- Tumor Suppression: This cell-cycle arrest effectively stops cellular proliferation and induces senescence or apoptosis (cell death) in estrogen receptor-positive breast cancer cells. Furthermore, it crosses the blood-brain barrier, showing clinical activity in patients with intracranial metastases.
Dosage & Administration
Oral Administration for Adults:
- Combination Therapy Dose: 150 mg taken orally twice daily when used in combination with fulvestrant or an aromatase inhibitor.
- Monotherapy Dose: 200 mg taken orally twice daily when used as a single agent.
- Administration: Tablets should be taken at approximately the same time each day, with or without food.
- Method: Swallow tablets whole. Do not chew, crush, or split the tablets.
- Missed Dose: If a patient vomits or misses a dose, the next dose should be taken at its regularly scheduled time; a double dose should not be taken.
Drug Interactions
- Strong CYP3A4 Inhibitors: Co-administration (e.g., Ketoconazole, Claritromycin) increases abemaciclib exposure. If unavoidable, reduce the Abemaxen dose to 100 mg twice daily.
- Strong CYP3A4 Inducers: Avoid co-administration (e.g., Rifampin, Phenytoin) as they can significantly decrease Abemaxen plasma levels and reduce efficacy.
- Grapefruit Products: Avoid consuming grapefruit juice or grapefruit products, as they can alter drug metabolism and increase the risk of toxicity.
Contraindications
- Hypersensitivity: Known severe hypersensitivity to Abemaciclib or any inactive ingredients listed in the formulation.
- Pregnancy: Categorized as a known risk to fetal development.
Side Effects
Patients receiving Abemaxen 150 mg may experience:
- Gastrointestinal: Diarrhea (most common, usually occurring during the first month), nausea, vomiting, and decreased appetite.
- Hematological: Neutropenia, leukopenia, anemia, and thrombocytopenia.
- Systemic: Fatigue, infections (such as upper respiratory tract infections), abdominal pain, and dizziness.
- Vascular: Increased risk of venous thromboembolism (blood clots) and deep vein thrombosis.
Pregnancy & Lactation
- Pregnancy: Can cause fetal harm. Females of reproductive potential must use effective contraception during treatment and for at least 3 weeks after the final dose.
- Lactation: Advise lactating women not to breastfeed during treatment and for at least 3 weeks after the last dose due to safety concerns for the infant.
Precautions & Warnings
- Diarrhea Management: Severe diarrhea can lead to dehydration. At the first sign of loose stools, patients must start antidiarrheal therapy (e.g., loperamide) and increase fluids.
- Hematology Monitoring: Complete Blood Counts (CBC) should be monitored prior to the start of therapy, every 2 weeks for the first 2 months, and monthly thereafter.
- Hepatotoxicity: Monitor liver function tests (ALT, AST, Bilirubin) closely. Interrupt or reduce the dose if severe elevations occur.
- Interstitial Lung Disease (ILD): Monitor for pulmonary symptoms such as cough or dyspnea. Permanently discontinue if severe ILD/pneumonitis is confirmed.
Use in Special Populations
- Hepatic Impairment: For patients with severe hepatic impairment (Child-Pugh Class C), reduce the dosing frequency to once daily.
- Geriatric Use: No overall differences in safety or effectiveness have been observed compared to younger patients, but closer monitoring for toxicities is recommended.
Overdose Effects
Overdose may result in severe diarrhea, profound bone marrow suppression (neutropenia), and extreme fatigue. Treatment consists of immediate discontinuation of the medication and aggressive supportive therapies.
Storage
- Condition: Store at controlled room temperature (20°C to 25°C).
- Protection: Keep the medication in its original blister packaging or container to protect it from moisture and light. Keep out of reach of children.
Supplier Information
Onco Solution is a premier global oncology medicine supplier dedicated to bridging the gap in advanced cancer care. We ensure secure, reliable, and authentic global distribution of breakthrough therapies like Abemaxen 150 mg. For medical quotes or wholesale inquiries, visit www.oncosolution.com.
Manufacturer Information
Abemaxen 150 mg is manufactured by Everest Pharmaceuticals Ltd., a leading high-tech pharmaceutical company based in Bangladesh, recognized for its strict adherence to international standards in the production of specialized generic oncology medications.
